Aurinia Pharmaceuticals (AUPH) Net Income (2019 - 2026)

Aurinia Pharmaceuticals has reported Net Income for 8 years, with the latest figure at $34.4 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income rose 47.14% year-over-year to $34.4 million; the trailing twelve-month figure through Mar 2026 stood at $298.2 million (up 648.13% YoY), and the FY2025 full-year result was $287.2 million, up 4892.3% from the prior year.
• Net Income for Q1 2026 stood at $34.4 million, down from $210.7 million in the prior quarter.
• The five-year high for Net Income was $210.7 million in Q4 2025, with the low at -$37.6 million in Q1 2022.
• Historically, Net Income has averaged $8.3 million across 5 years, with a median of -$9.0 million in 2022.
• Annual changes were most pronounced in 2023 — Net Income plunged 49.59% — and 2025, when it surged 14168.72%.
• Aurinia Pharmaceuticals' Net Income stood at -$26.0 million in 2022, then retreated by 3.26% to -$26.9 million in 2023, then jumped by 105.5% to $1.5 million in 2024, then surged by 14168.72% to $210.7 million in 2025, then slumped by 83.7% to $34.4 million in 2026.
• The last three Net Income figures came in at $34.4 million (Q1 2026), $210.7 million (Q4 2025), and $31.6 million (Q3 2025), per Business Quant data.